OBJECTIVES: Pelvic (ovarian) serous carcinomas frequently contain p53 mutations. Recently, a candidate serous cancer precursor (the p53 signature) with p53 mutations and other features in common with serous cancer has been discovered in distal fallopian tube mucosa. This study examined the relationship of putative ovarian cancer risk factors with the presence of p53 signatures in women with BRCA mutations (BRCA+). METHODS: Fallopian tubes from 75 BRCA+ women were immunostained for p53 signatures and correlated with age at first childbirth, parity, oral contraceptive use, body mass index (BMI), and BRCA subtype (1 or 2). Statistical analysis was performed with the T-test or Chi-square analysis and logistic regression adjusting for age and parity. RESULTS: Thirty-eight percent of the tubes contained p53 signatures, which were significantly associated with older age at first childbirth (mean 30.8 vs. 28.4 years; p=0.04) and lower parity (mean 1.4 vs. 2.2; p=0.01) in univariate analyses. The unadjusted odds ratios were 3.8 (p-trend=0.04) for first childbirth>/=30 years versus <30 and 0.2 (p-trend=0.01) for parity >/= 3 versus nulliparous women. After adjusting for age and parity, the trend for age at first childbirth became non-significant (adjusted odds ratio 3.5; p-trend=0.15), while that for parity remained significant (adjusted odds ratio 0.2; p-trend 0.02). CONCLUSIONS: The p53 signature is significantly associated with lower parity and possibly higher age at first childbirth, further linking this entity to serous cancer via risk factors associated with ovulation. The p53 signature merits consideration as a surrogate marker for serous cancer risk.
OBJECTIVES:Pelvic (ovarian) serous carcinomas frequently contain p53 mutations. Recently, a candidate serous cancer precursor (the p53 signature) with p53 mutations and other features in common with serous cancer has been discovered in distal fallopian tube mucosa. This study examined the relationship of putative ovarian cancer risk factors with the presence of p53 signatures in women with BRCA mutations (BRCA+). METHODS:Fallopian tubes from 75 BRCA+women were immunostained for p53 signatures and correlated with age at first childbirth, parity, oral contraceptive use, body mass index (BMI), and BRCA subtype (1 or 2). Statistical analysis was performed with the T-test or Chi-square analysis and logistic regression adjusting for age and parity. RESULTS: Thirty-eight percent of the tubes contained p53 signatures, which were significantly associated with older age at first childbirth (mean 30.8 vs. 28.4 years; p=0.04) and lower parity (mean 1.4 vs. 2.2; p=0.01) in univariate analyses. The unadjusted odds ratios were 3.8 (p-trend=0.04) for first childbirth>/=30 years versus <30 and 0.2 (p-trend=0.01) for parity >/= 3 versus nulliparous women. After adjusting for age and parity, the trend for age at first childbirth became non-significant (adjusted odds ratio 3.5; p-trend=0.15), while that for parity remained significant (adjusted odds ratio 0.2; p-trend 0.02). CONCLUSIONS: The p53 signature is significantly associated with lower parity and possibly higher age at first childbirth, further linking this entity to serous cancer via risk factors associated with ovulation. The p53 signature merits consideration as a surrogate marker for serous cancer risk.
Authors: David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum Journal: Am J Surg Pathol Date: 2007-02 Impact factor: 6.394
Authors: B Modan; P Hartge; G Hirsh-Yechezkel; A Chetrit; F Lubin; U Beller; G Ben-Baruch; A Fishman; J Menczer; J P Struewing; M A Tucker; S Wacholder Journal: N Engl J Med Date: 2001-07-26 Impact factor: 91.245
Authors: John R McLaughlin; Harvey A Risch; Jan Lubinski; Pal Moller; Parviz Ghadirian; Henry Lynch; Beth Karlan; David Fishman; Barry Rosen; Susan L Neuhausen; Kenneth Offit; Noah Kauff; Susan Domchek; Nadine Tung; Eitan Friedman; William Foulkes; Ping Sun; Steven A Narod Journal: Lancet Oncol Date: 2007-01 Impact factor: 41.316
Authors: S A Narod; P Sun; P Ghadirian; H Lynch; C Isaacs; J Garber; B Weber; B Karlan; D Fishman; B Rosen; N Tung; S L Neuhausen Journal: Lancet Date: 2001-05-12 Impact factor: 79.321
Authors: Johnathan M Lancaster; C Bethan Powell; Noah D Kauff; Ilana Cass; Lee-May Chen; Karen H Lu; David G Mutch; Andrew Berchuck; Beth Y Karlan; Thomas J Herzog Journal: Gynecol Oncol Date: 2007-11 Impact factor: 5.482
Authors: Ann K Folkins; Elke A Jarboe; Aasia Saleemuddin; Yonghee Lee; Michael J Callahan; Ronny Drapkin; Judy E Garber; Michael G Muto; Shelley Tworoger; Christopher P Crum Journal: Gynecol Oncol Date: 2008-03-14 Impact factor: 5.482
Authors: Shelley S Tworoger; Kathleen M Fairfield; Graham A Colditz; Bernard A Rosner; Susan E Hankinson Journal: Am J Epidemiol Date: 2007-07-26 Impact factor: 4.897
Authors: Joseph W Carlson; Alexander Miron; Elke A Jarboe; Mana M Parast; Michelle S Hirsch; Yonghee Lee; Michael G Muto; David Kindelberger; Christopher P Crum Journal: J Clin Oncol Date: 2008-09-01 Impact factor: 44.544
Authors: Wa Xian; Alexander Miron; Michael Roh; Dana R Semmel; Yosuf Yassin; Judy Garber; Esther Oliva; Annekathryn Goodman; Karishma Mehra; Ross S Berkowitz; Christopher P Crum; Bradley J Quade Journal: J Pathol Date: 2010-01 Impact factor: 7.996
Authors: Melinda S Yates; Larissa A Meyer; Michael T Deavers; Molly S Daniels; Elizabeth R Keeler; Samuel C Mok; David M Gershenson; Karen H Lu Journal: Cancer Prev Res (Phila) Date: 2011-01-28
Authors: Eleanor Y Chen; Karishma Mehra; Mitra Mehrad; Gang Ning; Alexander Miron; George L Mutter; Nicholas Monte; Bradley J Quade; Frank D McKeon; Yosuf Yassin; Wa Xian; Christopher P Crum Journal: J Pathol Date: 2010-09 Impact factor: 7.996
Authors: Jennifer Aa Gubbels; Nick Claussen; Arvinder K Kapur; Joseph P Connor; Manish S Patankar Journal: J Ovarian Res Date: 2010-03-29 Impact factor: 4.234
Authors: Ann K Folkins; Aasia Saleemuddin; Leslie A Garrett; Judy E Garber; Michael G Muto; Shelley S Tworoger; Christopher P Crum Journal: Gynecol Oncol Date: 2009-07-16 Impact factor: 5.482